Combined and alone apoptotic effects of Ankaferd hemostat and silver nanoparticles on chronic myeloid leukemia (CML) cell line K562
Abstract
Purpose: This study aimed to evaluate the effects of Ankaferd hemostat (ABS; Ankaferd Blood Stopper®) and silver nanoparticles (AgNPs), alone or in combination, on human chronic myeloid leukemia (CML) cells.
Materials and methods: The cytotoxicity of ABS and AgNPs on K562 CML cells was assessed using the XTT assay, measuring cell viability over time and across different doses. The half maximal inhibitory concentration (IC50) was determined at 72 hours. Apoptosis-related gene expression was analyzed by Real-Time PCR, and oxidative stress was assessed by total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI).
Results: AgNPs reduced cell viability at higher doses, with the IC50 for 40 nm AgNPs being 107.8854 ppm at 72 hours. ABS reduced cell viability by 75% even at maximum dose. Significant changes (p<0.05) were observed in bcl-2, caspase-8 and CDK4 in the AgNPs group. In the ABS group, bcl-2, and CDK4 expressions were significantly elevated. The combined treatment increased caspase-8 and caspase-9 expressions, promoting apoptosis. No significant differences were found in TAS-TOS, but all groups showed higher oxidant activity compared to the control, with the combination group exhibiting the highest antioxidant effect.
Conclusion: ABS, a herbal treatment with minimal side effects, and AgNPs, a promising therapeutic agent, both showed potential in inhibiting tumor cells. Their combination enhanced apoptotic effects, warranting further investigation.
Keywords
Chronic myeloid leukemia, Ankaferd hemostat, silver nanoparticles, apoptosis, oxidative stress
References
- 1. Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531459/. Accessed January 16, 2023
- 2. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336-1343. doi:10.1038/leu.2015.73
- 3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. doi:10.3322/caac.21387
- 4. Snyder D. CML Chapter. Cancer Treat Res. 2021;181:97-114. doi:10.1007/978-3-030-78311-2_6
- 5. Schoepf AM, Gust R. Novel strategies to eradicate resistant cells in chronic myeloid leukemia. Future Med Chem. 2020;12(23):2089-2092. doi:10.4155/fmc-2020-0278
- 6. Çiftçiler R, Haznedaroglu İC. Ankaferd hemostat: from molecules to medicine. Turk J Med Sci. 2020;50(SI-2):1739-1750. doi:10.3906/sag-1908-161
- 7. Koçak E, Çelebier M, Haznedaroglu IC, Altınöz S. Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach. Biomed Res Int. 2019;2019:5268031. doi:10.1155/2019/5268031
- 8. Koluman A, Akar N, Malkan UY, Haznedaroglu IC. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids. Biomed Res Int. 2016;2016:8957820. doi:10.1155/2016/8957820
- 9. Islam MA, Jacob MV, Antunes E. A critical review on silver nanoparticles: From synthesis and applications to its mitigation through low-cost adsorption by biochar. J Environ Manage. 2021;281:111918. doi:10.1016/j.jenvman.2020.111918
- 10. Bruna T, Maldonado Bravo F, Jara P, Caro N. Silver Nanoparticles and Their Antibacterial Applications. Int J Mol Sci. 2021;22(13):7202. doi:10.3390/ijms22137202
